Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

Diebold Nixdorf isn't as well-known as BigBear.ai, but it could have better growth prospects. Recursion Pharmaceuticals' AI drug discovery gives it a shot at growing larger than BigBear.ai. 10 stocks ...

BigBear.ai (NYSE: BBAI) has taken investors on a rollercoaster ride in 2025. The good news, though, is that they're probably enjoying the ride these days. Shares of the artificial intelligence (AI) ...

BigBear.ai is bigger than both of these AI-focused companies now. That could change. Will BigBear.ai's momentum continue? Maybe. However, I think investors can do better. I predict that two stocks ...

The human faculty to generate an infinite set of structured expressions in language, present in most cultures and normal ontogeny, is the most substantial evidence of the human capacity for recursion.

While Artificial Intelligence (AI) has emerged as groundbreaking and significantly impacting various sectors and enhancing quality of life, the chasm between technological advancements and the law is ...

There is no significant difference in the effectiveness of how autistic and non-autistic people communicate, according to a new study, challenging the stereotype that autistic people struggle to ...

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community. Issues are used to track todos, bugs, feature requests, and more.